Lupin on Wednesday said it has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility in Nagpur.
The EIR was issued following an inspection conducted from September 8 to September 16, 2025. A VAI classification indicates that while certain objectionable conditions were observed, the USFDA does not intend to take or recommend any regulatory or administrative action at this stage.